2021
Dosimetric Comparison of Volumetric Modulated Arc Therapy with Tomotherapy Based Total Body Irradiation for Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation for Acute Lymphocytic Leukemia
Liveringhouse C, Robinson T, Garcia G, Peters J, Kim S, Latifi K. Dosimetric Comparison of Volumetric Modulated Arc Therapy with Tomotherapy Based Total Body Irradiation for Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation for Acute Lymphocytic Leukemia. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e303. DOI: 10.1016/j.ijrobp.2021.07.950.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationTotal body irradiationAcute lymphocytic leukemiaStem cell transplantationPulmonary toxicityVMAT patientsBody irradiationSixteen patientsCell transplantationLung doseLymphocytic leukemiaHigh-dose total body irradiationAcute grade 3 diarrheaDose total body irradiationThermoplastic immobilizationVMAT plansGrade 3 diarrheaGrade 4 mucositisMean heart doseMean kidney doseResults Sixteen patientsAcute grade 3Common adverse eventsMean lung doseLate pulmonary toxicity
2018
ATIM-08. A PHASE I TRIAL OF PEMBROLIZUMAB AND VORINOSTAT COMBINED WITH TEMOZOLOMIDE AND RADIATION THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA (NCT03426891)
Sahebjam S, Forsyth P, Tran N, Mokhtari S, Arrington J, Jaglal M, Etame A, Liu J, Wicklund M, Gatewood T, Macaulay R, Robinson T, Yu M. ATIM-08. A PHASE I TRIAL OF PEMBROLIZUMAB AND VORINOSTAT COMBINED WITH TEMOZOLOMIDE AND RADIATION THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA (NCT03426891). Neuro-Oncology 2018, 20: vi2-vi2. PMCID: PMC6216125, DOI: 10.1093/neuonc/noy148.005.Peer-Reviewed Original ResearchAdverse eventsPD-1/PD-L1 antibodiesDay 1Sequential dose-escalation cohortsOngoing phase I trialDose level 2Dose-escalation cohortsCommon adverse eventsDose level 1Phase II doseMonth survival ratePD-L1 antibodiesPhase I trialDose-escalation designPrimary study objectiveTumor immune recognitionPre-clinical experimentsEligible ptsMaintenance temozolomideSafety cohortConcurrent radiotherapySecondary endpointsEscalation cohortsI trialEscalation design